Trials / Completed
CompletedNCT02312011
A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study will test the safety, tolerability, and pharmacokinetics of multiple escalating doses of ISIS-DMPKRx administered subcutaneously to adult patients with DM1.
Detailed description
This is a Phase 1/2a multicenter, blinded, placebo-controlled study of ISIS-DMPK Rx in adult patients with DM1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IONIS-DMPKRx | Drug |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-07-01
- Completion
- 2016-08-01
- First posted
- 2014-12-09
- Last updated
- 2022-12-06
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02312011. Inclusion in this directory is not an endorsement.